Ditch Partners With The CRIQ, Investissement Québec's World-Renowned Laboratory, For Nonclinical Testing

MONTREAL, QC/January, 2022 – Ditch Labs, Inc.’s partnership with the CRIQ led by Research Director and Partner Christelle Luce, Co-Founder and CTO Olivier Bourbonnais and Pharmacologist Mehdi El Hassani, will serve the objective of characterizing the aerosol generated by the DitchPen™. The company intends to present a toxicology report to the FDA and Health Canada in order to receive a Clinical Trial Authorization (Health Canada) and an Investigational New Drug approval (FDA).

Ditch Completes Successful Integration And Testing Of Its Second-Generation Alpha Product, Ready For Nonclinical Testing

MONTREAL, QC/January, 2022 – Ditch Labs, Inc. completing the successful integration and testing of its second-generation alpha product marks a green status for the upcoming nonclinical testing. The new alpha prototypes led by Co-Founder and CTO Olivier Bourbonnais and Hardware Expert François Bélanger include newer designs optimized for manufacturing along with a more effective mechanism allowing the device to be more accurate.